MicroTech Medical (Hangzhou) Co Ltd

MicroTech Medical (Hangzhou) Co Ltd has a basic and diluted share count of 416,064,000 shares, indicating no immediate dilution pressure from share issuance. However, liquidity risk could not be assessed due to the absence of balance-sheet inputs and no going-concern language in source documents. The company's valuation snapshot is not available, limiting the ability to assess its relative value in the industry.

Profitability and returns metrics are not available for the company, making it difficult to compare its performance against industry_config preferred metrics or cohort medians. Without these metrics, it is not possible to determine whether the company is outperforming or underperforming its peers in terms of return on invested capital (ROIC), operating margins, or other key profitability indicators.

The company's segments and geographic exposure are not disclosed in the available data, which limits the ability to assess revenue concentration or geographic diversification. This lack of information also prevents a detailed analysis of the company's exposure to regional economic or regulatory risks.

The company's growth trajectory is not quantified in the available data, as no outlook numeric deltas or revenue history are provided. Analysts have assigned a mean price target of 11.65 CNY, with a median price target of 11.65 CNY, and a mean recommendation of 3.00 (indicating a "Hold" rating). No strong buy or buy recommendations have been issued, with only one hold recommendation reported.

Risk factors include the inability to assess liquidity risk, which could impact the company's ability to meet short-term obligations. The dilution risk is currently low, but the absence of valuation and capital structure data limits the ability to assess the company's long-term financial health. No adjustments have been applied to the valuation metrics, and no dilution potential is reported in the available data.

Recent events, including filings and transcripts, are not disclosed in the available data, which limits the ability to assess the company's recent strategic or operational developments. Analysts have not issued strong buy or buy recommendations, and the company's outlook remains neutral based on the current price target and recommendation data.

Revenue ¥660.8M, +91,2% YoY; Operating income +170,4% YoY.

• ▍Revenue ¥660.8M, +91,2% YoY
• ▍Operating income +170,4% YoY
• ▍Net income +163,6% YoY
• ▍Net margin 6.1%

Revenue ¥345.6M, +36,5% YoY; Operating income +48,1% YoY.

• ▍Revenue ¥345.6M, +36,5% YoY
• ▍Operating income +48,1% YoY
• ▍Net income +49,5% YoY
• ▍Free cash flow +6,0% YoY
• ▍Net margin -18.3%

Revenue ¥253.2M, +45,9% YoY; Operating income −244,2% YoY.

• ▍Revenue ¥253.2M, +45,9% YoY
• ▍Operating income −244,2% YoY
• ▍Net income −256,8% YoY
• ▍Free cash flow −162,1% YoY
• ▍Net margin -49.4%

Revenue ¥173.6M, +14,7% YoY; Operating income +27,4% YoY.

• ▍Revenue ¥173.6M, +14,7% YoY
• ▍Operating income +27,4% YoY
• ▍Net income +27,2% YoY
• ▍Free cash flow +7,2% YoY
• ▍Net margin -20.2%

Revenue ¥151.4M; Operating income -¥48.1M.

• ▍Revenue ¥151.4M
• ▍Operating income -¥48.1M
• ▍Net margin -31.8%